Faecalibacterium prausnitzii Is Associated With Clinical Response to Immune Checkpoint Inhibitors in Patients With Advanced Gastric Adenocarcinoma: Results of Microbiota Analysis of PRODIGE 59-FFCD 1707-DURIGAST Trial
2024 · Gastroenterology · 12 citations
https://doi.org/10.1053/j.gastro.2024.10.020